Background Classification of risk of ischemic stroke is important for medical care and public health reasons. Whether addition of biomarkers adds to predictive power of the Framingham Stroke Risk or other traditional risk factors has not been studied in older women.
Introduction
Accurate stroke risk classification is useful for clinicians to apply to their patients, as well as for public health purposes. Most studies consider prediction and classification of overall cardiovascular disease (CVD) risk, which includes both coronary heart disease and stroke. Few studies focus specifically on stroke, and few consider stroke risk in older women, which is important because in women (but not in men) stroke accounts for a higher proportion of total CVD events than does coronary artery disease (1) .
The Framingham risk score, described by Kannel et al. in 1976 (2) , and its subsequent modifications in 1991 (3, 4) , have been widely used and validated as a general CVD risk profile. The Framingham risk prediction models specific for stroke [Framingham Stroke Risk Score (FSRS)] used Cox proportional hazards regression models (3) to relate age, systolic blood pressure, diabetes mellitus, cigarette smoking, prior cardiovascular disease, atrial fibrillation, left ventricular hypertrophy (LVH) by electrocardiogram, and the use of antihypertensive medication to the occurrence of stroke. The FSRS has limited predictive accuracy and as new biomarkers become available, it is of interest whether they improve risk prediction, or reclassify individuals to lower or higher risk groups better than do traditional risk factors (TRF) or than the FSRS.
In this report, we examine the additive predictive value of high-sensitivity C-reactive protein (hs-CRP) and lipoproteinassociated phospholipase A2 (Lp-PLA2), when added to the FSRS and TRF by looking at several indices of discrimination and of reclassification efficacy. These biomarkers are of special interest because high levels of these biomarkers have been independently associated with increased stroke risk (5, 6) and because they are commercially available for use by clinicians.
Methods
The study population in which CRP and Lp-PLA2 were assayed came from the Women's Health Initiative Observational Study (WHI-OS) which is an ongoing prospective study of the major determinants of morbidity and mortality in 93 676 postmenopausal women ages 50-79 at baseline, who were enrolled from October 1993 through December 1998 in 40 clinical centers in the United States, with methods and baseline characteristics described in detail elsewhere (7, 8) .
In brief, WHI eligibility required that the women had no medical conditions associated with predicted survival of less than three-years and gave written informed consent. The Hormones and Biomarkers Predicting Stroke (HaBPS) casecontrol study was nested in the WHI-OS after excluding 11 085 women who had a history of prior stroke or myocardial infarction (MI) or did not have sufficient blood samples for the biomarker assays, or after local adjudications for stroke were not confirmed centrally by trained neurologist adjudicators (n = 627 of the 11 085 exclusions). Among the remaining 82 591 eligible WHI-OS participants, the first 972 centrally adjudicated ischemic strokes were considered cases, and controls were selected in a time-forward manner, with one control for each case from the risk set at the time of the case's event.
Matching was done on age at screening (Ϯ2 years), race/ ethnicity (White, Black, Hispanic, Asian, American Indian, Other/unspecified), date of study enrollment (Ϯ3 months), and follow-up time (control follow-up time Ն case follow-up time). Cases and controls were pulled from separate datasets, so cases could not be selected as controls. Mean follow-up in controls was 7·9 years, standard deviation (SD) was 1·3 years, and range from 1·9 to 10·5 years.
Data and variables
At the WHI baseline visit, women completed questionnaires about medical history, lifestyle factors and personal habits, had a physical examination, and provided blood samples. Certified staff measured height and weight and right arm blood pressure, using the average of two-seated readings, after a fiveminute rest, and obtained at least 30 s apart. Blood pressure was measured before the blood draw or a minimum of 30 mins after the blood draw. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
Laboratory measures
Fasting blood samples, collected at the WHI baseline visit, were labeled, centrifuged, and frozen on site in -70C freezers and later shipped to the central WHI specimen repository (McKesson BioServices, Rockville, MD) for long-term storage. The case and control samples were extracted from the specimen archive and sent to Medical Research Laboratory International (MRL) for assay of hs-CRP, fasting plasma glucose as well as triglycerides, HDL-C and total cholesterol. From these measures, low-density lipoprotein cholesterol (LDL-C) was calculated for those women who had a triglyceride value less than 400. Low-density lipoprotein cholesterol values were set to missing for those women whose triglyceride value was >400 (n = 35) or who were missing HDL, total cholesterol, or triglyceride values (n = 7). Samples were sent to the laboratory at diaDexus Inc. (South San Francisco, CA) for assay of Lp-PLA2. These laboratory tests were performed between September 2005 and March 2006, approximately seven-to 12 years since specimen collection (depending on when participants were enrolled).
Lipoprotein-associated phospholipase A2 mass was measured in plasma aliquots using an enzyme-linked immunoassay (PLAC™ test, diaDexus Inc.). Samples were incubated in microtitre plate wells with immobilized monoclonal antibody (2C10) against Lp-PLA2. The enzyme was identified by a second monoclonal anti-Lp-PLA2 antibody (4B4) labeled with horseradish peroxidase. The standard was recombinant Lp-PLA2. The range of detection was 50-1000 ng/ml and the interassay coefficients of variation were 7·8% at 276 ng/ml, 6·1% at 257 ng/ml, and 13·5% at 105 ng/ml. There was no cross-reactivity with other A2 phospholipases. All analyses were performed blinded to risk factors, biochemical, and clinical characteristics. 2telephone follow-up, and participant or third-party reports. For a potential stroke case, laboratory results, medical records, and available imaging study reports were obtained. Trained local physician adjudicators assigned a diagnosis according to standard criteria, and all locally adjudicated strokes were sent for central adjudication by three highly trained neurologists. Only centrally confirmed ischemic strokes were used in this study and only stroke events that required hospitalization were considered as a potential outcome; transient ischemic attacks or hemorrhagic strokes (determined on review of reports of brain imaging studies) were not included in the definition of stroke outcome. Ischemic stroke was defined as the rapid onset of a persistent neurologic deficit without evidence for other causes, attributed to an obstruction in the arterial circulation to the brain. The deficit must have lasted more than 24 h unless death supervened, or there was a demonstrable lesion compatible with acute stroke on computed tomography or magnetic resonance imaging scan. Additional details are provided elsewhere (9) .
Statistical analyses
The objective of the statistical analyses was to determine if the two commercially available assays, hs-CRP and Lp-PLA2, add predictive value over and above the FSRS or TRF and if they reclassify individuals into a different risk category. To evaluate the utility of these assays for risk stratification, we first calculated unconditional logistic regression to obtain odds ratio for stroke risk using the variables from the FSRS for women (3) . The FSRS variable included: age, systolic blood pressure, being on antihypertensive medications, history of diabetes, smoking, atrial fibrillation, LVH, and prevalent CVD. In Framingham, CVD includes history of MI, angina pectoris, coronary insufficiency, intermittent claudication, or congestive heart failure (CHF), but in our data set, those with history of MI were excluded. We also assume no LVH for all women because the LVH variable was not available in our data set and because the prevalence of LVH is low. We then calculated unconditional logistic regression estimates for stroke risk adding each of the biomarkers in their continuous form (log-transformed hs-CRP or Lp-PLA2) one at a time, and also together, to the model with the variables used in the FSRS equation.
In order to classify participants into absolute risk categories from the above models, we had to adopt methods used in prospective studies to our case-control study (10, 11) . To calculate predicted probabilities of stroke with and without the biomarker, we added the term: log p p n n controls cases 1 − ⋅ ⎛ ⎝ ⎜ ⎞ ⎠ ⎟ to the intercept of the unconditional logistic regression models; p was estimated as the incidence of stroke in the parent study (the WHI-OS), which was 0·0029 annually, times the average follow-up of eight-years. Because this was generally a low to intermediate risk population (by virtue of the fact that we excluded all those with a previous stroke or MI), the risk categories we chose were: <2%, 2% to <5%, 5% to <8%, and Ն8%. These categories roughly correspond to low, intermediate, and high risk levels used in decisions to initiate treatment to prevent stroke in persons with atrial fibrillation (12) .
Similarly, we added each biomarker one at a time and both together to models with TRF variables generally available to clinicians' age, race, current smoking, systolic blood pressure, self-reported current blood pressure medication use, self-reported history of diabetes, self-reported history of atrial fibrillation, self-reported history of vascular disease (angina, revascularization, peripheral vascular disease, or CHF), BMI, alcohol use (none, <7, 7, or more drinks per week), self-reported depression, current hormone therapy use, and low-density lipoprotein, triglycerides. We included triglycerides because in the HaBPS study it was found that high triglyceride levels increase risk (unpublished data) and triglyceride levels are also usually readily available to clinicians.
We assessed various indices of additive predictability of two biomarkers, as proposed by Pencina et al. (10) . 1. Discrimination as measured by the C-statistic reflecting the area under the curve from a receiver operating characteristic curve (which is a plot of sensitivity on y-axis vs. 1-specificity on x-axis). It is the probability that a randomly selected person with the event will have a higher predicted risk than a randomly selected person without an event. Higher C-statistic values indicate better discrimination. 2. The integrated discrimination improvement (IDI) measures the separation between people who develop the outcome and those who do not, by comparing the average predicted risks for people who develop the outcome and those who do not (7) . Smaller P-values for IDI indicate better discrimination. Integrated discrimination improvement is the difference in the mean predicted probability of being a case and being a control in the model with the new biomarker minus the difference in the mean predicted probability of being a case and being a control in the model without the new biomarker: 
where p is the mean predicted probability.
Net reclassification improvement (NRI) index which meas-
ures whether the new model with the biomarker included, sufficiently changes a person's risk to move them into a different risk category and thus potentially affect treatment decisions. It distinguishes between individuals correctly and incorrectly reclassified and quantifies the correct movement in categories (upward for events and downward for non-events). The NRI is calculated as: 4. Category-less NRI. As noted by Pencina et al. (10, 11) , one drawback of the reclassification-based measure is its dependence on the choice of absolute risk categories. This limitation can be best addressed by using a category-less NRI or an IDI. The category-less NRI is the percent of all subjects whose risk estimates are changed in the correct direction (increased risk in model with biomarker compared to model without biomarker for cases and decreased risk for controls) minus the percent changed in the incorrect direction (decreased risk in model with biomarker compared to model without biomarker for cases and increased risk for controls). It is calculated as: 
Results
There were 902 centrally adjudicated stroke cases and 909 controls who met our criteria of no prior stroke or MI, and adequate blood samples for Lp-PLA2 and hs-CRP assays. Because of missing covariate information models using FSRS, variables were limited to 1751 (868 cases and 883 controls).
Since the TRF models had more covariates, these models were limited further to 1625 participants with non-missing data (794 cases and 831 controls). Stroke cases compared to controls were more likely at baseline to be current smokers, to have cardiovascular comorbidities, diabetes, higher BMI, systolic blood pressure, triglycerides, hs-CRP levels, and Lp-PLA2 levels ( Table 1 ; P-values are for unmatched data). Table 2 summarizes the C-statistic and IDI for all models. It should be noted that the FSRS alone has a rather low C-statistic of 0·644 indicating it is not a very good discriminator. Adding the two biomarkers singly or jointly does not affect the C-statistic appreciably. The IDI was highly significant for hs-CRP, (P < .001), for Lp-PLA2 (P = .001), and for both biomarkers together (P < .001.). Table 3 illustrates an example calculation of the NRI based on the FSRS for 868 cases and 883 controls. There are eight cases with calculated FSRS corresponding to a less than 2% risk of stroke over eight-years (first row of the table). After adding log of hs-CRP to the Framingham model, there are 19 cases at a less than 2% risk. The numbers on the diagonal indicate that these individuals did not change their risk category with the addition of log hs-CRP to the model. Cases above the diagonal (n = 112 out of the 868 strokes or 12·9%), correctly moved up at least one risk category and cases below the diagonal (78 out of 868 = 9·0%) incorrectly moved down in risk. Thus the net improvement for cases was 12·9-9·0% = 3·9%. Among controls, adding the biomarkers resulted in 116 controls moving down in risk correctly (13·1%) and 95 controls incorrectly moving up in risk (10·8%) resulting in a net difference of 2·3%. Thus the NRI is 3·9% + 2·3% = 6·3% (after rounding). Table 4 displays number and percent of cases and controls that moved in the correct and incorrect direction of risk and the associated NRI. Adding log hs-CRP to the FSRS results in an NRI of 6·3% (P = < 0·01), with 12·9% of the cases and 13·1% of the controls being correctly reclassified. The corresponding figures for adding Lp-PLA2 were 4·3% for cases and 3·1% for controls being correctly reclassified. Similar relationships pertained to the TRF.
The category-less NRI with hs-CRP was 18·9% [95% confidence interval (CI) 9·5, 28·3] and 15·2% (95% CI 5·5, 24·9) in the FSRS and TRF models, respectively. NRI with Lp-PLA2 was 8·4% (95% CI -0·9, 17·8) and 9·8% (95% CI 0·1, 19·5) for FSRS and TRF, respectively (data not shown). It should be noted that under the null hypothesis, the NRI is expected to be 0%.
We also did analyses stratified by hormone use, LDL-C levels, stroke subtype, and time of stroke after baseline. There were no differences in reclassification when we stratified by current vs. non-current hormone use at baseline, or LDL level (i.e. LDL < 130 vs. those with LDL Ն 130; data not shown). However, after stratifying by stroke subtype, ( Table 5) we found that hs-CRP aids in reclassification of cardioembolic strokes with an NRI of 12·0% (95% CI 4·3-19·6%), while Lp-PLA2 aids in reclassification of large artery strokes with an NRI of 19·8% (95% CI 7·4-32·1%). The category-less NRI, (which measures the percent of people moving in risk in the right direction without regard to the magnitude of the change in risk), is 26·6% for hs-CRP for cardioembolic strokes and 30·3% for Lp-PLA2 for large artery strokes. Both hs-CRP and Lp-PLA2 showed a significantly increased NRI for strokes occurring less than three-years after baseline than for later strokes ( Table 5 ). The NRI for the early strokes was 7·9% (95% CI 0·8-14·9%) for hs-CRP and 5·8% (95% CI 0·4-11·2%). for Lp-PLA2.
Discussion
We have found in a case-control study of 868 ischemic strokes and 883 controls in postmenopausal women that the addition of hs-CRP to a model with FSRS variables, overall modestly improved risk prediction and significantly increased the C-statistic, the IDI, and the NRI and substantially improved risk prediction for cardioemoblic strokes and for strokes occurring less than three-years after baseline. While the addition of Lp-PLA2 to Framingham variables or TRF overall did not result in a higher net reclassification improvement among all women, it did significantly and substantially improve risk prediction for large artery strokes and early strokes compared to those occurring after three-years.
A potential limitation of our study is its case-control rather than prospective design. However, we used statistical corrections to adapt methods used in prospective studies to our case-control study, as suggested by Pencina et al. (11) . In addition, generalizability may be limited because our sample is predominantly White (86%) and excludes women with any prior history of stroke or MI. The strengths of our study include large numbers of ischemic strokes (n = 868), rigorous ascertainment and adjudication of stroke cases by trained neurologists, high quality of phenotypic data in WHI, availability of the two biomarkers which can be commercially measured and thus may be useful to clinicians, and the different indices we used in exploring the additive usefulness of biomarkers in risk prediction.
Because a large proportion of all strokes occur in people with no standard risk factors for stroke, a biomarker that adds to prediction of risk may be very useful. The Jupiter trial (14) indicated that people with normal or even low levels of LDL but who had elevated hs-CRP benefited from statin therapy by having lower rates of cardiovascular events, with risk of stroke reduced by 48% among those on rosuvastatin compared to placebo. Our finding that hs-CRP improves the risk prediction of ischemic stroke in older women, particularly cardioembolic strokes and early strokes, is consistent with the implications of this study and suggests that this biomarker may be useful in assessing stroke risk more accurately than Framingham risk factors or TRF alone. Lipoprotein-associated phospholipase A2 was useful in improving stroke risk prediction for large artery strokes and early strokes. The role of Lp-PLA2 in prediction of large artery strokes is consistent with a report by Koledgie et al. (15) , which shows a relationship of Lp-PLA2 to plaque progression in coronary arteries, and a report by Serruys et al. (16) , which demonstrates that a specific Lp-PLA2 inhibitor stabilizes the plaque necrotic core that is a key determinant of plaque vulnerability. The reclassification improvement with both of these biomarkers for early strokes compared to later occurring strokes implies that they are more acute predictors.
In summary, we found that hs-CRP may be useful to improve stroke risk prediction overall in older women, and particularly for cardioembolic strokes, while Lp-PLA2 has additive predictive value above the FSRS for large artery strokes. Both biomarkers are useful for prediction of more acute strokes than for those occurring later.
